Condition: Wound Healing Time · Total Hip Arthroplasty (THA) · Sponsor: Clinical Center of Vojvodina
Surgical wound complications following primary total hip arthroplasty remain a significant clinical challenge despite advances in wound care technologies. The optimal choice of dressing and frequency of dressing changes remain insufficiently investigated, particularly regarding their influence on wound healing and the wound microenvironment. This prospective, randomized, controlled clinical trial aims to evaluate the impact of dressing type and dressing change frequency on surgical wound healing in patients undergoing primary total hip arthroplasty. Ninety patients will be allocated into three treatment groups receiving either a capillary-action dressing system (VACUTEX™) or standard dressings with different dressing change intervals. The study will assess time to complete wound epithelialization, postoperative wound complications, pain intensity, wound temperature, exudate pH, length of hospital stay, and time to suture removal. In addition, the study will investigate the potential role of wound temperature and exudate pH as early indicators of impaired healing and postoperative complications.
This description comes directly from the study's public registry record.
Andrijana Ćorić, MScN · +381611810756 · 912007d23@mf.uns.ac.rs
Nemanja Gvozdenović, PhD, Associate Professor · +381646355614 · nemanja.gvozdenovic@mf.uns.ac.rs
Always discuss trial participation with your own doctor first.
| Clinic for Orthopedic Surgery and Traumatology, University Clinical Center of Vojvodina | Novi Sad, Serbia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07655388